Although the prevalence of HER2 amplification in CRCs is relatively lower than in other cancers, detecting HER2 amplification in CRCs becomes inevitable for selecting patients who may benefit from HER2-targeted therapy. This evidence concerns the gene ERBB2 and cancer.